The North Carolina gene therapy company Asklepios BioPharmaceutical (named after the Greek god of medicine, and known as “AskBio” for short) announced Thursday that it had raised $235 milllion. That, even by the standards of the foamy, frothy market for closely held biotechnology startups, is a lot of money, especially in a field that, despite all the excitement, has yet to yield a commercial hit.

But the fundraising round is worth attention for other reasons — because it tells us something about where things may be headed for biotech companies, and for private biotechs, in particular, which stand to benefit if they can leverage certain advantages the way AskBio has.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy